Renpho

Longevity investing has “come of age” says MMC founder

Latest articles

The Sheekey Science Show: NAD+ rejuvenation strategies

NAD+ metabolism in aging & three strategies to rejuvenate. Welcome to The Sheekey Science Show! Longevity.Technology is delighted to partner with YouTube sensation Eleanor Sheekey (interviewed...

JUVICELL sets sights on lifespan and healthspan

Ten ingredients, one capsule. JUVICELL is on a mission to deliver an all-in-one longevity supplement. Far from just supplementing their diet to ensure an adequate...

New NAD+ boosting longevity supplement hits the market

Elevant Prime dietary supplement contains a “high purity” form of NMN that has completed safety and toxicology testing. New York based health and wellness brand...

BioAge kicks off Phase 2 longevity clinical trial

Company reveals primary indicator for BGE-117 clinical trial is unexplained anaemia of aging. Hot on the heels of its monster $90 million Series C funding...

Most read

JUVICELL sets sights on lifespan and healthspan

Ten ingredients, one capsule. JUVICELL is on a mission to deliver an all-in-one longevity supplement. Far from just supplementing their diet to ensure an adequate...

New NAD+ boosting longevity supplement hits the market

Elevant Prime dietary supplement contains a “high purity” form of NMN that has completed safety and toxicology testing. New York based health and wellness brand...

Is nicotinamide riboside a safe and effective way to combat aging?

ChromaDex executive highlights the importance of clinical studies to prove the benefits of NAD+ boosting compound. ChromaDex is the company behind the popular healthy aging...
Apollo Neuro

Editor's picks

The Sheekey Science Show: NAD+ rejuvenation strategies

NAD+ metabolism in aging & three strategies to rejuvenate. Welcome to The Sheekey Science Show! Longevity.Technology is delighted to partner with YouTube sensation Eleanor Sheekey (interviewed...

JUVICELL sets sights on lifespan and healthspan

Ten ingredients, one capsule. JUVICELL is on a mission to deliver an all-in-one longevity supplement. Far from just supplementing their diet to ensure an adequate...

New NAD+ boosting longevity supplement hits the market

Elevant Prime dietary supplement contains a “high purity” form of NMN that has completed safety and toxicology testing. New York based health and wellness brand...
Renpho

McKenny-McFarlane Capital is focused on bridging the communication gap between longevity investing and longevity companies.

An investment firm with its sights firmly locked on longevity investing, McKenny-McFarlane Capital (MMC) was founded in 2020 and has already made an impression with its “longevity investment as a service” model. The company counts longevity biopharma powerhouse Life Biosciences as a client, among others, and has already worked on several investment opportunities in the sector, representing close to $50 million worth of interest.

Longevity.Technology: As interest in our sector continues to grow, we are seeing the emergence of investment firms with an exclusive focus on longevity. MMC is an interesting new player in the space and the company has made significant progress in a short space of time. We caught up with the firm’s founding partner, Daragh Summerfield, to learn more about MMC’s approach.

Having worked in finance for more than 15 years, Summerfield and his partner at MMC, Fiona McFarlane, at the request of their network, developed an interest in technology investments that could help make the world a better place. They first started to become aware of the longevity opportunity about four years ago, popularised through the work of Dr David Sinclair, author of the book Lifespan: Why We Age — and Why We Don’t Have To and co-founder of Life Biosciences.

 


“When we started seeing the science that was coming out of the industry, we realised longevity had come of age and could become a mainstream asset class,” says Summerfield.

 


 

The MMC partners then started work on looking at the kinds of disruptive opportunities presented by longevity, which they knew that the investors in their network would be very interested in.

“We started realising that a confluence of scientific breakthroughs is now enabling these longevity treatments, many of which have only really been around for a few years,” says Summerfield. “From CRISPR, to genome sequencing, to complex peptide molecule manufacturing techniques and new nanoparticle delivery models. The resulting landscape is so compelling, it just completely consumed us.”

“Today, we are working with Life Biosciences and other companies as well – essentially delivering longevity investment as a service.”

MMC has an extensive network of high-net-worth individuals and family office firms interested in the disruptive opportunities presented by the longevity sector. The company’s approach is essentially as a broker between the scientists, who often don’t understand what investors are looking for, and the investors, who often don’t have the scientific expertise to be able to screen all the opportunities and filter out the best ones.

 


 

“The more you drill into the detail of longevity, the more you realise that there’s not going to be one silver bullet, there will be many …”

 


 

“So when filtering the opportunities, we pay attention to companies that have good synergies.”

MMC likes companies with a combination of a discovery platform, which provides a pipeline of new treatments or application areas, and a fast-track route to approval, such as targeting orphan disease states. In this space, the firm does not focus on companies at a specific stage, and Summerfield cites one client that is still in academia, while pointing out that Life Biosciences is at Series C level.

“Our added value is to communicate the huge benefits within this exciting and quick paced sector,” he adds.

There’s a lot of work involved in that, Summerfield says, because the way that scientists present their research is often not the story investors want to hear in order to make longevity investing decisions.

“There’s a big chasm that has to be crossed there, and you have to build the bridge from both sides,” he adds. “You have to educate the investors, and also work with the academics to get the story, structure and execution path right in order to lower the risks and make it a good investment.”

 


 

For start-ups raising money, MMC adds value by streamlining the fundraising process.

 


 

“What they like about us is that they can have one conversation with us and we understand it,” says Summerfield. “We then produce materials; it could be video interviews, sector analysis, investment briefs, investor Q&A documents, etc. We do the heavy lifting, and eventually, we come back with tangible interest. There’s a lot of satisfaction in that.”

longevity explainer

What excites Summerfield most about longevity investing is its focus on health, rather than disease.

“The breakthrough change is that we’re no longer treating diseases, we’re treating the causes of diseases,” he says. “The reason we love this sector so much is that the scientists are going upstream to understand the processes that are already part of healthy organisms, mechanisms that are naturally keeping us youthful in early years, processes that are repairing us all the time, things that are rejuvenating us all the time.”

But MMC is conscious that this also presents one of longevity’s biggest communication problems when it comes to investors.

“Longevity research offers an incredible array of new health possibilities,” says Summerfield. “Its scope has everyone excited, but in the same breath it confuses many about what the sector symbolises. We still meet investors who don’t quite understand it. Thankfully, the science in the sector and its growth will turn it into the longevity boom we know it will be.”

 

Comment on this article

Danny Sullivan
Contributing Editor Danny has worked in technology communications for more than 15 years, spanning Europe and North America. From bionics and lasers to software and pharmaceuticals – and everything in between – he’s covered it all. Danny has wide experience of technology publishing and technical writing and has specific interest in the transfer from idea to market.
Renpho

Most popular

JUVICELL sets sights on lifespan and healthspan

Ten ingredients, one capsule. JUVICELL is on a mission to deliver an all-in-one longevity supplement. Far from just supplementing their diet to ensure an adequate...

New NAD+ boosting longevity supplement hits the market

Elevant Prime dietary supplement contains a “high purity” form of NMN that has completed safety and toxicology testing. New York based health and wellness brand...

Is nicotinamide riboside a safe and effective way to combat aging?

ChromaDex executive highlights the importance of clinical studies to prove the benefits of NAD+ boosting compound. ChromaDex is the company behind the popular healthy aging...

It’s time to sit up and take notice of mitochondria

CohBar CEO on the development of a “true portfolio” of mitochondria based therapeutics. US biotech company CohBar is developing mitochondria-based therapeutics for the treatment of...
Apollo Neuro

Related articles

Leading NAD+ company ChromaDex announces $25m raise

LA-based company ChromaDex announces that it has entered into a securities purchase agreement for the sale of $25m of its common stock in a...

Andreessen Horowitz leads $7m seed funding: Bold

Digital health and wellness company bags $7 million in seed funding led by Andreessen Horowitz. Bold focuses on disease prevention and healthy aging. Using personalised and...

Charles River to acquire Cognate BioServices for $875m

Charles River Laboratories signs $875 million cash deal to acquire cell and gene manufacturer Cognate BioServices. Charles River has announced plans to acquire Cognate BioServices,...

$1.1B biotech SPAC good news for longevity

Bioengineered human tissue company Humacyte nears biotech SPAC deal to go public. Humacyte, a transformative biotech platform company capable of manufacturing universally-implantable bioengineered human tissue...

The trillion dollar upside to longevity

New economic model estimates that targeting aging has larger economic gains than eradicating individual diseases: time for a policy pivot? Although life expectancy has increased...
TruNigen pf